Type 2 & other diabetes

Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter ‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial

Diabetes Obes MetabPublished Randomised crossover trial

Authors' conclusion

Supplementation of pioglitazone could alleviate canagliflozin-induced ketone bodies. This benefit may be closely associated with decreased substrate NEFAs rather than other factors including glucagon, fasting insulin and NA.

Study context

Population
Non-obese patients with T2D treated with the SGLT2i canagliflozin; mean age 49 ± 7.97 years, BMI 25.35 ± 2.22 kg/m²1 discontinued in washout
Participants
25 patients
Comparison
Pioglitazone plus canagliflozin vs canagliflozin monotherapy
Primary endpoint
Change (Δ) in β-hydroxybutyric acid (β-HBA) before and after treatment
Follow-up
4 weeks per treatment period
Methodological detailssingle-centre, two periods of 4 weeks, 4-week washout, randomized 1:1
  • Single-centre
  • Two periods of 4 weeks
  • 4-week washout
  • Randomized 1:1

Primary result

As reported in the abstract

Δβ-HBA

PIOG + CANA

219.84

± 80.21 · μmol/L

CANA

317.69

± 83.07 · μmol/L

P < 0.001

Secondary outcomes

OutcomePIOG + CANACANAP value
ΔacetoneSignificantly smaller with PIOG + CANA8.98 ± 4.17 μmol/L12.29 ± 5.27 μmol/LP = 0.018

Δacetoacetate

Difference between groups not significant for acetoacetate

Rate of conversion into urinary ketones

Elevated after both interventions

NEFA, glucagon, glucagon to insulin ratio and noradrenaline

Significantly increased after both CANA and PIOG + CANA; only non-esterified fatty acids (NEFAs) differed significantly between groups

Correlation of ΔNEFA with Δketones

Difference in ΔNEFA significantly associated with differences in Δβ-HBA and Δacetoacetate

Original publication

Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter ‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial. Diabetes Obes Metab. Published 3 May 2024. doi:10.1111/dom.15641

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.